Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor...
Saved in:
| Published in | Molecular cancer Vol. 17; no. 1; pp. 38 - 14 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
19.02.2018
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1476-4598 1476-4598 |
| DOI | 10.1186/s12943-018-0777-1 |
Cover
Loading…
| Abstract | Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) are a favorable predictive factor for EGFR tyrosine kinase inhibitors (TKIs) treatment. For lung cancer patients with EGFR-exon 19 deletions or an exon 21 Leu858Arg mutation, the standard first-line treatment is first-generation (gefitinib, erlotinib), or second-generation (afatinib) TKIs. EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with EGFR mutant lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been reported. Optimal treatment for the various mechanisms of acquired resistance is not yet clearly defined, except for the T790M mutation. Repeated tissue biopsy is important to explore resistance mechanisms, but it has limitations and risks. Liquid biopsy is a valid alternative to tissue re-biopsy. Osimertinib has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKI. For other TKI-resistant mechanisms, combination therapy may be considered. In addition, the use of immunotherapy in lung cancer treatment has evolved rapidly. Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment. |
|---|---|
| AbstractList | Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor receptor (
EGFR
) in non-small cell lung cancer (NSCLC) are a favorable predictive factor for EGFR tyrosine kinase inhibitors (TKIs) treatment. For lung cancer patients with
EGFR
-exon 19 deletions or an exon 21 Leu858Arg mutation, the standard first-line treatment is first-generation (gefitinib, erlotinib), or second-generation (afatinib) TKIs. EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with
EGFR
mutant lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been reported. Optimal treatment for the various mechanisms of acquired resistance is not yet clearly defined, except for the T790M mutation. Repeated tissue biopsy is important to explore resistance mechanisms, but it has limitations and risks. Liquid biopsy is a valid alternative to tissue re-biopsy. Osimertinib has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKI. For other TKI-resistant mechanisms, combination therapy may be considered. In addition, the use of immunotherapy in lung cancer treatment has evolved rapidly. Understanding and clarifying the biology of the resistance mechanisms of
EGFR
-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment. Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) are a favorable predictive factor for EGFR tyrosine kinase inhibitors (TKIs) treatment. For lung cancer patients with EGFR-exon 19 deletions or an exon 21 Leu858Arg mutation, the standard first-line treatment is first-generation (gefitinib, erlotinib), or second-generation (afatinib) TKIs. EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with EGFR mutant lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been reported. Optimal treatment for the various mechanisms of acquired resistance is not yet clearly defined, except for the T790M mutation. Repeated tissue biopsy is important to explore resistance mechanisms, but it has limitations and risks. Liquid biopsy is a valid alternative to tissue re-biopsy. Osimertinib has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKI. For other TKI-resistant mechanisms, combination therapy may be considered. In addition, the use of immunotherapy in lung cancer treatment has evolved rapidly. Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment. Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) are a favorable predictive factor for EGFR tyrosine kinase inhibitors (TKIs) treatment. For lung cancer patients with EGFR-exon 19 deletions or an exon 21 Leu858Arg mutation, the standard first-line treatment is first-generation (gefitinib, erlotinib), or second-generation (afatinib) TKIs. EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with EGFR mutant lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been reported. Optimal treatment for the various mechanisms of acquired resistance is not yet clearly defined, except for the T790M mutation. Repeated tissue biopsy is important to explore resistance mechanisms, but it has limitations and risks. Liquid biopsy is a valid alternative to tissue re-biopsy. Osimertinib has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKI. For other TKI-resistant mechanisms, combination therapy may be considered. In addition, the use of immunotherapy in lung cancer treatment has evolved rapidly. Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment. Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) are a favorable predictive factor for EGFR tyrosine kinase inhibitors (TKIs) treatment. For lung cancer patients with EGFR-exon 19 deletions or an exon 21 Leu858Arg mutation, the standard first-line treatment is first-generation (gefitinib, erlotinib), or second-generation (afatinib) TKIs. EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with EGFR mutant lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been reported. Optimal treatment for the various mechanisms of acquired resistance is not yet clearly defined, except for the T790M mutation. Repeated tissue biopsy is important to explore resistance mechanisms, but it has limitations and risks. Liquid biopsy is a valid alternative to tissue re-biopsy. Osimertinib has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKI. For other TKI-resistant mechanisms, combination therapy may be considered. In addition, the use of immunotherapy in lung cancer treatment has evolved rapidly. Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment.Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) are a favorable predictive factor for EGFR tyrosine kinase inhibitors (TKIs) treatment. For lung cancer patients with EGFR-exon 19 deletions or an exon 21 Leu858Arg mutation, the standard first-line treatment is first-generation (gefitinib, erlotinib), or second-generation (afatinib) TKIs. EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with EGFR mutant lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been reported. Optimal treatment for the various mechanisms of acquired resistance is not yet clearly defined, except for the T790M mutation. Repeated tissue biopsy is important to explore resistance mechanisms, but it has limitations and risks. Liquid biopsy is a valid alternative to tissue re-biopsy. Osimertinib has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKI. For other TKI-resistant mechanisms, combination therapy may be considered. In addition, the use of immunotherapy in lung cancer treatment has evolved rapidly. Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment. Abstract Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) are a favorable predictive factor for EGFR tyrosine kinase inhibitors (TKIs) treatment. For lung cancer patients with EGFR-exon 19 deletions or an exon 21 Leu858Arg mutation, the standard first-line treatment is first-generation (gefitinib, erlotinib), or second-generation (afatinib) TKIs. EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with EGFR mutant lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been reported. Optimal treatment for the various mechanisms of acquired resistance is not yet clearly defined, except for the T790M mutation. Repeated tissue biopsy is important to explore resistance mechanisms, but it has limitations and risks. Liquid biopsy is a valid alternative to tissue re-biopsy. Osimertinib has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKI. For other TKI-resistant mechanisms, combination therapy may be considered. In addition, the use of immunotherapy in lung cancer treatment has evolved rapidly. Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment. |
| ArticleNumber | 38 |
| Audience | Academic |
| Author | Wu, Shang-Gin Shih, Jin-Yuan |
| Author_xml | – sequence: 1 givenname: Shang-Gin surname: Wu fullname: Wu, Shang-Gin – sequence: 2 givenname: Jin-Yuan surname: Shih fullname: Shih, Jin-Yuan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29455650$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1UttqFTEUHaRiL_oBvkjAF1-m5jKZzLwIpbT1YEWQ-hz2yexMU2Ymp0mm0Df_wT_0S8x4WukRJZBsstdarL1Zh8Xe5CcsiteMHjPW1O8j420lSsqakiqlSvasOGCVqstKts3ek3q_OIzxhlKmGlW9KPYzTcpa0oOi_wwT9DjilIi3BMzt7AJ2JGB0McFkkCRPzi7Ov5KrT6uf338kCD2mjEjXGGBzT9xEoLtbkB3J_so4wjAQg_ka5qknZmmFl8VzC0PEVw_vUfHt_Ozq9GN5-eVidXpyWZpsM5WVqTkTLbUcgeZKWWyEaiVtsVWWcuCMcYOmEzUiiJpTShsrOa4ZX-e2OCpWW93Ow43eBDdCuNcenP794UOvISRnBtSNkLyxdUdNLSvTCpAVYtcCF9JSoWTW-rDV2szrETuTdxRg2BHd7UzuWvf-TstmWTTNAu8eBIK_nTEmPbq4bAYm9HPU2X0l2qqlIkPfbqE9ZGtusj4rmgWuT7JNRqkUPKOO_4HKp8PRmRwO6_L_DuHN0xH-eH8MQAaoLcAEH2NAq41LkJxfJnKDZlQvUdPbqOkcNb1ETbPMZH8xH8X_z_kFW_LUxQ |
| CitedBy_id | crossref_primary_10_1016_j_bbcan_2023_188967 crossref_primary_10_12677_ACM_2022_123258 crossref_primary_10_3389_fonc_2023_1293441 crossref_primary_10_1007_s00204_019_02453_2 crossref_primary_10_2147_JIR_S313056 crossref_primary_10_3390_ijms25042316 crossref_primary_10_4132_jptm_2020_08_13 crossref_primary_10_1016_j_xinn_2021_100103 crossref_primary_10_3389_fcell_2021_669132 crossref_primary_10_1158_2326_6066_CIR_20_0080 crossref_primary_10_1097_CAD_0000000000001707 crossref_primary_10_1136_bmjopen_2022_062036 crossref_primary_10_1016_j_tranon_2021_101204 crossref_primary_10_1016_j_bbamcr_2021_119016 crossref_primary_10_1016_j_jpha_2024_101154 crossref_primary_10_1177_15347354241307006 crossref_primary_10_1155_2018_2349021 crossref_primary_10_3389_fonc_2022_836117 crossref_primary_10_2147_CMAR_S364713 crossref_primary_10_1016_j_cpccr_2022_100199 crossref_primary_10_3389_fimmu_2023_1265865 crossref_primary_10_3390_cancers14205144 crossref_primary_10_1371_journal_pone_0226853 crossref_primary_10_1111_1759_7714_14753 crossref_primary_10_1038_s41419_019_2020_4 crossref_primary_10_1007_s12094_023_03370_8 crossref_primary_10_1016_j_prp_2024_155213 crossref_primary_10_1016_j_cpccr_2023_100228 crossref_primary_10_1186_s43046_021_00067_3 crossref_primary_10_18632_aging_204957 crossref_primary_10_4274_ahot_galenos_2024_2024_10_5 crossref_primary_10_1186_s12885_022_10095_4 crossref_primary_10_3390_cancers12123804 crossref_primary_10_1007_s10495_021_01694_w crossref_primary_10_3389_fonc_2022_933925 crossref_primary_10_1007_s00432_023_05468_6 crossref_primary_10_1007_s12094_022_02936_2 crossref_primary_10_1186_s12885_021_08977_0 crossref_primary_10_3390_cancers13215320 crossref_primary_10_3348_kjr_2022_0295 crossref_primary_10_2174_1574892818666230316145232 crossref_primary_10_1002_cncr_31382 crossref_primary_10_1016_j_bcp_2024_116207 crossref_primary_10_1007_s00018_022_04647_x crossref_primary_10_3389_fphar_2024_1382787 crossref_primary_10_1080_03007995_2019_1676708 crossref_primary_10_2147_DDDT_S275123 crossref_primary_10_1016_j_matdes_2023_112336 crossref_primary_10_1155_2024_5437090 crossref_primary_10_1186_s13046_021_02137_9 crossref_primary_10_1016_j_drudis_2025_104321 crossref_primary_10_1515_med_2023_0727 crossref_primary_10_3390_cancers13236005 crossref_primary_10_1016_j_biopha_2020_110965 crossref_primary_10_4236_jct_2024_155022 crossref_primary_10_1186_s13046_019_1207_y crossref_primary_10_3390_ijms24108878 crossref_primary_10_1016_j_bmc_2025_118146 crossref_primary_10_1002_cbf_4072 crossref_primary_10_1016_j_fitote_2020_104590 crossref_primary_10_3389_fonc_2022_804212 crossref_primary_10_1016_j_lungcan_2020_04_022 crossref_primary_10_2147_IJGM_S350771 crossref_primary_10_1093_icvts_ivy107 crossref_primary_10_1177_1758835920974192 crossref_primary_10_1002_prp2_1047 crossref_primary_10_3389_fonc_2024_1397238 crossref_primary_10_3390_jpm14070752 crossref_primary_10_1016_j_phymed_2024_155690 crossref_primary_10_1002_cam4_6545 crossref_primary_10_1016_j_bbrc_2022_12_029 crossref_primary_10_1016_j_ejca_2019_10_019 crossref_primary_10_1186_s12943_022_01670_1 crossref_primary_10_1155_2022_6295934 crossref_primary_10_3389_fonc_2021_720819 crossref_primary_10_1038_s41389_022_00400_y crossref_primary_10_1007_s10637_023_01356_5 crossref_primary_10_1016_j_bbrc_2020_07_111 crossref_primary_10_3390_cancers14205073 crossref_primary_10_3389_fgene_2022_791675 crossref_primary_10_1038_s41419_018_1162_0 crossref_primary_10_1111_cas_14032 crossref_primary_10_1097_CAD_0000000000000771 crossref_primary_10_1515_med_2020_0014 crossref_primary_10_3390_cancers13246228 crossref_primary_10_1002_cbic_202000179 crossref_primary_10_3389_fphar_2018_00849 crossref_primary_10_1016_j_bbcan_2024_189194 crossref_primary_10_1016_j_jtho_2021_07_011 crossref_primary_10_1136_bmj_l5460 crossref_primary_10_1097_CAD_0000000000001505 crossref_primary_10_1111_1759_7714_14713 crossref_primary_10_1155_2022_1178874 crossref_primary_10_1158_2159_8290_CD_21_0715 crossref_primary_10_1016_j_pccm_2023_04_006 crossref_primary_10_3390_pharmaceutics11080376 crossref_primary_10_1038_s41598_021_95985_6 crossref_primary_10_1089_cbr_2022_0049 crossref_primary_10_3389_fphar_2022_918317 crossref_primary_10_2298_SARH231114015L crossref_primary_10_1016_j_critrevonc_2020_103008 crossref_primary_10_1080_21655979_2021_1936891 crossref_primary_10_1007_s00204_020_02816_0 crossref_primary_10_1186_s12890_024_02905_1 crossref_primary_10_1016_j_drup_2021_100770 crossref_primary_10_1111_1759_7714_13959 crossref_primary_10_1371_journal_pone_0256139 crossref_primary_10_1016_j_phrs_2023_106739 crossref_primary_10_1111_cas_15036 crossref_primary_10_1080_13880209_2023_2292266 crossref_primary_10_2174_1566524019666191001113511 crossref_primary_10_1111_cas_15151 crossref_primary_10_1021_acs_analchem_4c03914 crossref_primary_10_1111_cas_14180 crossref_primary_10_3389_fphar_2020_00891 crossref_primary_10_3389_fonc_2021_751209 crossref_primary_10_3389_fphar_2023_1093017 crossref_primary_10_3724_abbs_2024106 crossref_primary_10_1080_14740338_2018_1549222 crossref_primary_10_1002_cam4_7420 crossref_primary_10_3389_fcell_2022_815596 crossref_primary_10_1038_s41419_020_03047_y crossref_primary_10_3389_fimmu_2022_975246 crossref_primary_10_1016_j_chmed_2023_05_004 crossref_primary_10_1177_17588359231222604 crossref_primary_10_1016_j_bcp_2021_114516 crossref_primary_10_1016_j_drup_2022_100821 crossref_primary_10_17116_onkolog20211006156 crossref_primary_10_3389_fimmu_2021_782775 crossref_primary_10_2147_CMAR_S309924 crossref_primary_10_1002_cbic_201900270 crossref_primary_10_1111_cas_15721 crossref_primary_10_1016_j_canlet_2024_216762 crossref_primary_10_3390_cancers14184522 crossref_primary_10_1158_1078_0432_CCR_22_2781 crossref_primary_10_1186_s12931_023_02329_1 crossref_primary_10_1186_s12885_023_10735_3 crossref_primary_10_1016_j_tips_2019_10_004 crossref_primary_10_1158_0008_5472_CAN_22_3059 crossref_primary_10_3390_cancers14194562 crossref_primary_10_1097_PAI_0000000000000965 crossref_primary_10_1038_s41388_021_01889_0 crossref_primary_10_1186_s12964_023_01082_8 crossref_primary_10_1007_s00432_024_05992_z crossref_primary_10_1177_17588359241289648 crossref_primary_10_1016_j_clon_2025_103776 crossref_primary_10_1002_ijc_33853 crossref_primary_10_3389_fonc_2023_1107631 crossref_primary_10_1002_ptr_8130 crossref_primary_10_1002_cam4_6870 crossref_primary_10_3389_fonc_2021_621422 crossref_primary_10_3389_fonc_2020_00472 crossref_primary_10_3892_ol_2019_10427 crossref_primary_10_1007_s13402_022_00694_5 crossref_primary_10_1016_j_heliyon_2023_e15812 crossref_primary_10_1038_s41598_019_39965_x crossref_primary_10_3390_cancers14143511 crossref_primary_10_1007_s11547_023_01722_6 crossref_primary_10_1093_pcmedi_pbaa028 crossref_primary_10_37349_etat_2023_00156 crossref_primary_10_2217_pgs_2018_0038 crossref_primary_10_3389_fimmu_2022_1024755 crossref_primary_10_12793_tcp_2021_29_e17 crossref_primary_10_1016_j_crad_2024_02_016 crossref_primary_10_1016_j_canlet_2020_10_048 crossref_primary_10_1111_cas_14655 crossref_primary_10_1155_2022_5687832 crossref_primary_10_3389_fonc_2021_664290 crossref_primary_10_3892_etm_2023_12187 crossref_primary_10_3389_fphar_2018_00558 crossref_primary_10_1146_annurev_med_100223_090016 crossref_primary_10_1155_2021_9311875 crossref_primary_10_3892_ol_2019_10643 crossref_primary_10_1016_j_tranon_2020_100954 crossref_primary_10_1016_j_lungcan_2022_05_011 crossref_primary_10_1002_ctm2_515 crossref_primary_10_1002_ctm2_876 crossref_primary_10_1007_s13770_019_00232_9 crossref_primary_10_1631_jzus_B2200465 crossref_primary_10_1038_s41698_024_00757_w crossref_primary_10_1111_1759_7714_13366 crossref_primary_10_1515_cclm_2024_0614 crossref_primary_10_3390_ijms231810415 crossref_primary_10_1007_s11051_024_06008_0 crossref_primary_10_1158_1078_0432_CCR_23_2357 crossref_primary_10_1016_j_procbio_2023_05_024 crossref_primary_10_1038_s41419_022_04655_6 crossref_primary_10_3389_fsurg_2022_865040 crossref_primary_10_1016_j_carbpol_2021_118655 crossref_primary_10_1016_j_ejmech_2024_116470 crossref_primary_10_1016_j_bbrc_2019_11_050 crossref_primary_10_12998_wjcc_v9_i18_4617 crossref_primary_10_1631_jzus_B2200292 crossref_primary_10_1002_cbin_12230 crossref_primary_10_1158_1535_7163_MCT_19_0168 crossref_primary_10_1016_j_jpha_2021_06_002 crossref_primary_10_3389_fcell_2022_805507 crossref_primary_10_3389_fphar_2021_731895 crossref_primary_10_3390_cancers13040922 crossref_primary_10_3389_fmolb_2022_847835 crossref_primary_10_2217_fon_2021_1406 crossref_primary_10_3390_biomedicines10020277 crossref_primary_10_1002_advs_202002922 crossref_primary_10_1016_j_ejps_2021_105815 crossref_primary_10_1038_s41598_020_61727_3 crossref_primary_10_1002_ijc_34507 crossref_primary_10_1183_16000617_0294_2020 crossref_primary_10_3390_ph17050626 crossref_primary_10_1016_j_actbio_2025_02_012 crossref_primary_10_1186_s40164_023_00386_2 crossref_primary_10_1002_ctm2_813 crossref_primary_10_1007_s10637_023_01341_y crossref_primary_10_1007_s40265_022_01695_2 crossref_primary_10_3390_cancers12010040 crossref_primary_10_1007_s10528_024_10961_9 crossref_primary_10_1155_2022_6962163 crossref_primary_10_1177_10732748221081360 crossref_primary_10_1038_s41416_021_01696_0 crossref_primary_10_1007_s40487_022_00209_0 crossref_primary_10_1002_cbin_11359 crossref_primary_10_3389_fonc_2024_1470827 crossref_primary_10_4236_jct_2022_137040 crossref_primary_10_1038_s41598_021_87094_1 crossref_primary_10_1007_s40264_018_0772_x crossref_primary_10_3389_fgene_2022_968376 crossref_primary_10_3390_genes15121624 crossref_primary_10_1208_s12249_019_1332_0 crossref_primary_10_20960_revcancer_00034 crossref_primary_10_3390_ijms24108794 crossref_primary_10_1097_MD_0000000000032169 crossref_primary_10_1016_j_omto_2022_02_011 crossref_primary_10_3390_ijms22105181 crossref_primary_10_1002_bit_27964 crossref_primary_10_7555_JBR_38_20240045 crossref_primary_10_1186_s13578_023_01101_8 crossref_primary_10_3389_fonc_2021_619013 crossref_primary_10_1007_s11864_018_0570_9 crossref_primary_10_3389_fonc_2020_00656 crossref_primary_10_1186_s12967_024_05423_0 crossref_primary_10_2174_0929867331666230815115111 crossref_primary_10_1016_j_jtho_2022_06_002 crossref_primary_10_1111_1759_7714_15042 crossref_primary_10_2174_1574892816666210615161501 crossref_primary_10_1186_s12885_023_10909_z crossref_primary_10_3389_fimmu_2024_1512468 crossref_primary_10_3389_fonc_2022_1017026 crossref_primary_10_3389_fonc_2023_1279822 crossref_primary_10_1016_j_jtho_2024_11_032 crossref_primary_10_1186_s12943_023_01780_4 crossref_primary_10_3389_fphar_2022_928983 crossref_primary_10_1016_j_bbrc_2023_09_047 crossref_primary_10_1186_s12885_021_08228_2 crossref_primary_10_2147_OTT_S428707 crossref_primary_10_3389_fonc_2022_911362 crossref_primary_10_2174_1574892818666221201145810 crossref_primary_10_3389_fmolb_2025_1548810 crossref_primary_10_1016_j_bioorg_2024_107390 crossref_primary_10_3390_app112210526 crossref_primary_10_1038_s41598_024_53622_y crossref_primary_10_2147_IJGM_S348912 crossref_primary_10_1007_s10147_018_1378_0 crossref_primary_10_1038_s41467_024_47606_9 crossref_primary_10_5507_bp_2022_037 crossref_primary_10_3390_cancers14143362 crossref_primary_10_3389_fonc_2021_691915 crossref_primary_10_3390_ijms252211954 crossref_primary_10_1074_jbc_RA119_007784 crossref_primary_10_1016_j_annonc_2024_02_003 crossref_primary_10_1016_j_biopha_2019_108995 crossref_primary_10_1038_s41388_023_02673_y crossref_primary_10_1097_MD_0000000000029629 crossref_primary_10_2174_0929867329666220117114306 crossref_primary_10_3390_cancers15215169 crossref_primary_10_3390_cancers14020309 crossref_primary_10_1016_j_cca_2020_07_003 crossref_primary_10_32604_oncologie_2022_027545 crossref_primary_10_3389_fpubh_2022_985834 crossref_primary_10_3892_ijmm_2020_4562 crossref_primary_10_1016_j_bbagen_2018_06_006 crossref_primary_10_1016_j_bbadis_2018_10_015 crossref_primary_10_1002_cam4_70078 crossref_primary_10_2217_fon_2022_0919 crossref_primary_10_3390_cancers15123076 crossref_primary_10_1080_10717544_2021_2021321 crossref_primary_10_1016_j_omtn_2020_09_015 crossref_primary_10_3390_cancers14225582 crossref_primary_10_3233_CBM_210281 crossref_primary_10_3389_fendo_2022_833929 crossref_primary_10_1007_s11523_023_00975_5 crossref_primary_10_1038_s41401_021_00638_z crossref_primary_10_1186_s12964_022_00840_4 crossref_primary_10_1016_j_flm_2018_08_002 crossref_primary_10_1097_CM9_0000000000002468 crossref_primary_10_1097_MD_0000000000035081 crossref_primary_10_1186_s13046_019_1486_3 crossref_primary_10_1186_s13046_018_0901_5 crossref_primary_10_3390_genes15040468 crossref_primary_10_1097_MD_0000000000024393 crossref_primary_10_1097_MD_0000000000026450 crossref_primary_10_3389_fimmu_2022_1022598 crossref_primary_10_3892_ol_2024_14637 crossref_primary_10_1007_s11010_020_03854_z crossref_primary_10_1016_j_lungcan_2023_107194 crossref_primary_10_4143_crt_2022_381 crossref_primary_10_1186_s12943_022_01534_8 crossref_primary_10_2147_OTT_S246606 crossref_primary_10_3389_fonc_2022_819674 crossref_primary_10_3389_fcell_2021_677860 crossref_primary_10_3390_biomedicines11051490 crossref_primary_10_1038_s41392_024_01868_3 crossref_primary_10_1016_j_ejmech_2025_117442 crossref_primary_10_1186_s13046_024_03184_8 crossref_primary_10_3390_pharmaceutics13050630 crossref_primary_10_3389_fimmu_2022_846402 crossref_primary_10_2174_1389203723666220530102720 crossref_primary_10_62347_TCEC1867 crossref_primary_10_3389_fchem_2022_837987 crossref_primary_10_1002_prm2_12051 crossref_primary_10_3390_cancers14143323 crossref_primary_10_1007_s11060_025_04938_w crossref_primary_10_2147_OTT_S254464 crossref_primary_10_3233_CBM_190201 crossref_primary_10_1002_bab_2401 crossref_primary_10_3389_fphar_2022_926890 crossref_primary_10_1016_j_bbrc_2024_150200 crossref_primary_10_3389_fonc_2020_01481 crossref_primary_10_26416_OnHe_68_3_2024_10151 crossref_primary_10_1007_s10637_023_01329_8 crossref_primary_10_1016_j_currproblcancer_2021_100722 crossref_primary_10_3892_ol_2023_13909 crossref_primary_10_1111_1440_1681_13860 crossref_primary_10_3390_cancers13143421 crossref_primary_10_1016_j_crad_2021_02_012 crossref_primary_10_3892_ol_2020_11858 crossref_primary_10_3389_fonc_2023_1208403 crossref_primary_10_1111_jcmm_17799 crossref_primary_10_1038_s41598_022_23655_2 crossref_primary_10_2217_fon_2021_0064 crossref_primary_10_3390_cancers14143550 crossref_primary_10_3389_fphar_2024_1428158 crossref_primary_10_3389_fonc_2020_585292 crossref_primary_10_3389_fmed_2022_1102550 crossref_primary_10_1016_j_mcpro_2023_100624 crossref_primary_10_1038_s41419_021_04485_y crossref_primary_10_3390_diagnostics13010129 crossref_primary_10_1007_s00249_022_01594_0 crossref_primary_10_3389_fimmu_2023_1332057 crossref_primary_10_1183_16000617_0145_2023 crossref_primary_10_1111_1759_7714_15212 crossref_primary_10_1007_s11547_022_01569_3 crossref_primary_10_1016_j_ejmcr_2025_100251 crossref_primary_10_1111_1759_7714_14141 crossref_primary_10_1016_j_jtho_2020_09_001 crossref_primary_10_1111_1759_7714_14261 crossref_primary_10_1016_j_cpt_2024_07_001 crossref_primary_10_1038_s41598_023_43982_2 crossref_primary_10_3892_ol_2023_14098 crossref_primary_10_1007_s00109_023_02384_7 crossref_primary_10_3390_cancers11111775 crossref_primary_10_1016_j_jtocrr_2020_100010 crossref_primary_10_3390_jpm12030404 crossref_primary_10_1016_j_jtho_2024_02_001 crossref_primary_10_1096_fj_201903220R crossref_primary_10_1111_bph_15360 crossref_primary_10_2217_imt_2020_0148 crossref_primary_10_3390_ijms23148025 crossref_primary_10_1186_s12964_024_01876_4 crossref_primary_10_1155_2022_1112987 crossref_primary_10_2174_1871520620666200508090515 crossref_primary_10_1177_1758835921992968 crossref_primary_10_1016_j_bbcan_2020_188363 crossref_primary_10_3390_cancers14194894 crossref_primary_10_1186_s13045_024_01601_1 crossref_primary_10_2174_0113892037291318240130103348 crossref_primary_10_1016_j_talanta_2023_124564 crossref_primary_10_1021_acs_jctc_0c01244 crossref_primary_10_1038_s41392_022_00947_7 crossref_primary_10_1038_s41401_022_00930_6 crossref_primary_10_1016_j_tube_2020_102039 crossref_primary_10_3390_jcm11010124 crossref_primary_10_1016_j_bcp_2023_115690 crossref_primary_10_1016_j_lungcan_2024_107555 crossref_primary_10_3390_ijms20225701 crossref_primary_10_1073_pnas_2317790121 crossref_primary_10_1038_s41698_022_00292_6 crossref_primary_10_1111_1759_7714_12961 crossref_primary_10_1016_j_jff_2023_105845 crossref_primary_10_1097_CAD_0000000000001436 crossref_primary_10_1016_j_jtocrr_2021_100171 crossref_primary_10_1038_s41388_021_01696_7 crossref_primary_10_3389_fonc_2022_902353 crossref_primary_10_3892_ijo_2020_5103 crossref_primary_10_1038_s41419_019_1601_6 crossref_primary_10_1007_s00259_023_06174_8 crossref_primary_10_1136_jitc_2024_009165 crossref_primary_10_1016_j_phrs_2020_105110 crossref_primary_10_3389_fgene_2022_984575 crossref_primary_10_3390_ijms22179453 crossref_primary_10_1002_jbt_22900 crossref_primary_10_1016_j_intimp_2023_110001 crossref_primary_10_1186_s11671_021_03580_5 crossref_primary_10_1016_j_ejrad_2019_108780 crossref_primary_10_1016_j_phymed_2024_155872 crossref_primary_10_1007_s11684_022_0976_4 crossref_primary_10_1007_s11523_023_00946_w crossref_primary_10_1038_s41419_022_05050_x crossref_primary_10_1007_s11010_023_04907_9 crossref_primary_10_3892_or_2021_8114 crossref_primary_10_1620_tjem_2024_J002 crossref_primary_10_3390_ijms25031374 crossref_primary_10_1016_j_jconrel_2023_04_006 crossref_primary_10_1016_j_bioorg_2021_105325 crossref_primary_10_2147_OTT_S276837 crossref_primary_10_1016_j_actbio_2024_07_020 crossref_primary_10_1016_j_jtocrr_2021_100193 crossref_primary_10_1515_med_2021_0379 crossref_primary_10_3390_jcm9113543 crossref_primary_10_1016_j_drup_2022_100904 crossref_primary_10_2174_0115680096281231240202073558 crossref_primary_10_1186_s12890_022_01866_7 crossref_primary_10_3389_fimmu_2023_1161718 crossref_primary_10_1002_mco2_709 crossref_primary_10_1016_j_heliyon_2024_e27633 crossref_primary_10_1016_j_ctarc_2021_100345 crossref_primary_10_1088_1755_1315_276_1_012003 crossref_primary_10_1007_s12672_024_01133_7 crossref_primary_10_17116_onkolog20221101128 crossref_primary_10_1038_s41388_024_03220_z crossref_primary_10_2217_fon_2021_0934 crossref_primary_10_1038_s41420_024_01884_w crossref_primary_10_1016_j_mam_2025_101358 crossref_primary_10_1097_PAI_0000000000001008 crossref_primary_10_1002_1878_0261_12481 crossref_primary_10_1186_s13578_025_01358_1 crossref_primary_10_3389_fimmu_2025_1555216 crossref_primary_10_3390_cancers15051445 crossref_primary_10_3389_fonc_2020_590356 crossref_primary_10_1177_1758835920946156 crossref_primary_10_3892_ijmm_2019_4220 crossref_primary_10_2147_CMAR_S275874 crossref_primary_10_1038_s41401_024_01451_0 crossref_primary_10_1186_s12890_021_01800_3 crossref_primary_10_3390_pharmaceutics13091500 crossref_primary_10_1016_j_lungcan_2020_04_004 crossref_primary_10_1016_S1470_2045_20_30726_9 crossref_primary_10_1186_s13045_023_01509_2 crossref_primary_10_1016_j_omto_2021_05_005 crossref_primary_10_1016_j_canlet_2022_01_030 crossref_primary_10_1080_14796694_2024_2370186 crossref_primary_10_1186_s13045_022_01311_6 crossref_primary_10_1038_s41598_019_42245_3 crossref_primary_10_4103_crst_crst_61_21 crossref_primary_10_32604_oncologie_2022_022121 crossref_primary_10_3389_fonc_2023_1238883 crossref_primary_10_1021_acs_analchem_4c05111 crossref_primary_10_1016_j_pupt_2023_102227 crossref_primary_10_1080_07391102_2021_2023644 crossref_primary_10_1016_j_acra_2024_10_019 crossref_primary_10_1016_j_jddst_2023_104346 crossref_primary_10_1007_s12094_024_03533_1 crossref_primary_10_4103_CRST_CRST_51_19 crossref_primary_10_62347_RLVZ6860 crossref_primary_10_1089_cbr_2020_4395 crossref_primary_10_3390_pharmaceutics15041284 crossref_primary_10_1038_s41419_023_06069_4 crossref_primary_10_3390_medicina58070908 crossref_primary_10_3390_molecules27217466 crossref_primary_10_1016_j_jtocrr_2022_100322 crossref_primary_10_1016_j_lungcan_2023_107378 crossref_primary_10_1038_s41598_023_42985_3 crossref_primary_10_3390_cells11213434 crossref_primary_10_1186_s12575_023_00215_0 crossref_primary_10_3389_fonc_2023_1248690 crossref_primary_10_3390_cancers15102858 crossref_primary_10_1155_2022_6531748 crossref_primary_10_1016_j_phrs_2020_105007 crossref_primary_10_1097_CAD_0000000000001139 crossref_primary_10_3389_fphar_2024_1432490 crossref_primary_10_3390_cells10040716 crossref_primary_10_1186_s12885_024_13168_8 crossref_primary_10_3389_fgene_2023_1254839 crossref_primary_10_1007_s00432_023_05416_4 crossref_primary_10_1186_s12916_022_02692_8 crossref_primary_10_1186_s12943_022_01662_1 crossref_primary_10_1186_s13045_023_01430_8 |
| Cites_doi | 10.1038/nature22364 10.1158/2159-8290.CD-14-0337 10.3816/CLC.2010.n.046 10.1158/0008-5472.CAN-05-0331 10.1038/nature08622 10.1158/1078-0432.CCR-16-0399 10.1016/S1556-0864(16)30325-2 10.1073/pnas.0709662105 10.1056/NEJMoa1413654 10.1016/j.lungcan.2012.09.016 10.1097/JTO.0000000000000263 10.1200/JCO.2016.66.7162 10.1158/1535-7163.MCT-13-0966 10.1126/scitranslmed.3003726 10.1200/JCO.2017.35.15_suppl.9020 10.1056/NEJMoa1612674 10.1016/j.jmoldx.2013.03.001 10.1056/NEJMoa050753 10.1200/JCO.2009.24.7049 10.1056/NEJMoa044238 10.1158/1078-0432.CCR-15-1031 10.1097/JTO.0b013e3182745948 10.1111/bjd.15935 10.1200/JCO.2016.71.9096 10.1158/1078-0432.CCR-12-2246 10.1007/s00280-016-2992-z 10.1136/esmoopen-2016-000063 10.1158/1078-0432.CCR-11-1468 10.1056/NEJMoa011954 10.1016/S0140-6736(15)01281-7 10.1016/j.lungcan.2017.05.009 10.1158/2159-8290.CD-13-0314 10.1093/annonc/mdw326 10.1021/acs.jmedchem.6b01894 10.1016/S1470-2045(13)70604-1 10.1056/NEJMoa1411817 10.1016/j.jtho.2016.05.035 10.1097/JTO.0b013e31826913f7 10.1158/1078-0432.CCR-13-2482 10.1158/1078-0432.CCR-15-0560 10.18632/oncotarget.11303 10.3322/caac.21332 10.1186/s12916-017-0900-y 10.2217/bmm.16.6 10.1158/1078-0432.CCR-11-1712 10.1016/S1470-2045(14)71180-5 10.1016/j.jtho.2015.12.093 10.1016/j.lungcan.2017.07.006 10.1200/JCO.2012.44.2806 10.1200/JCO.2008.17.3930 10.1016/S1556-0864(16)30243-X 10.1164/rccm.201009-1440OC 10.21037/jtd.2016.07.96 10.1016/j.lungcan.2011.04.007 10.1056/NEJMe1500181 10.1016/S1470-2045(15)70124-5 10.1073/pnas.0710370104 10.1001/jama.2014.3741 10.1158/1078-0432.CCR-14-1190 10.1016/S1556-0864(16)30246-5 10.1634/theoncologist.2013-0168 10.1126/science.1141478 10.4161/cbt.24598 10.1093/annonc/mdx183 10.1038/onc.2008.109 10.1126/scitranslmed.3002003 10.1038/ng.2330 10.4143/crt.2012.44.3.151 10.1200/JCO.2009.26.7278 10.1200/JCO.2007.15.0375 10.1001/jamaoncol.2015.1066 10.18632/oncotarget.9931 10.1056/NEJMoa1616288 10.1158/1538-7445.AM2015-2586 10.1158/1078-0432.CCR-08-0151 10.1038/ncomms7377 10.1016/j.cell.2009.11.007 10.1186/1756-9966-32-50 10.6004/jnccn.2017.0050 10.1097/MD.0000000000006087 10.1200/JCO.2012.47.1102 10.1200/JCO.2017.73.9250 10.1158/2159-8290.CD-14-0326 10.1001/jamaoncol.2015.5009 10.1158/1078-0432.CCR-06-1570 10.18632/oncotarget.14613 10.3322/caac.21349 10.1001/jamaoncol.2014.257 10.1016/S1556-0864(16)30327-6 10.1001/jamaoncol.2015.4921 10.1158/1535-7163.TARG-15-B153 10.1016/j.ejca.2008.10.026 10.1073/pnas.0502860102 10.1056/NEJMc053610 10.1056/NEJMoa040938 10.1158/0008-5472.CAN-10-2668 10.1158/2159-8290.CD-12-0108 10.1097/JTO.0b013e318216ee52 10.1016/j.lungcan.2010.10.014 10.1016/j.jtho.2017.04.003 10.1126/science.1099314 10.1016/j.jtho.2016.11.510 10.1016/j.cllc.2013.10.001 10.1016/j.jfma.2017.04.018 10.1158/2159-8290.CD-13-0310 10.1002/ijc.24657 10.18632/oncotarget.7189 10.3892/ol.2013.1705 10.1056/NEJMoa1113205 10.1001/jamaoncol.2016.0173 10.1158/1078-0432.CCR-17-1447 10.1038/sj.bjc.6603949 10.1056/NEJMoa1507643 10.1016/j.lungcan.2014.08.016 10.1056/NEJMoa0810699 10.1126/scitranslmed.3002356 10.1158/1078-0432.CCR-15-3101 10.1056/NEJMc1602688 10.3892/or.2012.1987 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2018 BioMed Central Ltd. The Author(s). 2018 |
| Copyright_xml | – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: The Author(s). 2018 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s12943-018-0777-1 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1476-4598 |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_83528f6d0c654c93a54eed9a235f0375 PMC5817870 A528100532 29455650 10_1186_s12943_018_0777_1 |
| Genre | Journal Article Review |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- 0R~ 123 29M 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HH5 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PZZ RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c598t-4c621390f2ea02137fe8379509e97f02a2112cecd36eea3620008f52eb12b02a3 |
| IEDL.DBID | M48 |
| ISSN | 1476-4598 |
| IngestDate | Wed Aug 27 01:26:22 EDT 2025 Thu Aug 21 18:33:48 EDT 2025 Tue Aug 05 10:18:22 EDT 2025 Tue Jun 17 22:12:06 EDT 2025 Tue Jun 10 21:07:31 EDT 2025 Mon Jul 21 05:58:23 EDT 2025 Thu Apr 24 23:07:04 EDT 2025 Tue Jul 01 01:01:15 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c598t-4c621390f2ea02137fe8379509e97f02a2112cecd36eea3620008f52eb12b02a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12943-018-0777-1 |
| PMID | 29455650 |
| PQID | 2004394903 |
| PQPubID | 23479 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_83528f6d0c654c93a54eed9a235f0375 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5817870 proquest_miscellaneous_2004394903 gale_infotracmisc_A528100532 gale_infotracacademiconefile_A528100532 pubmed_primary_29455650 crossref_citationtrail_10_1186_s12943_018_0777_1 crossref_primary_10_1186_s12943_018_0777_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-02-19 |
| PublicationDateYYYYMMDD | 2018-02-19 |
| PublicationDate_xml | – month: 02 year: 2018 text: 2018-02-19 day: 19 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Molecular cancer |
| PublicationTitleAlternate | Mol Cancer |
| PublicationYear | 2018 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | C Abbosh (777_CR57) 2017; 545 GR Oxnard (777_CR62) 2014; 20 LV Sequist (777_CR98) 2016; 374 H Bai (777_CR123) 2009; 27 TH Chang (777_CR44) 2011; 183 M Gerlinger (777_CR49) 2012; 366 JH Schiller (777_CR2) 2002; 346 LV Sequist (777_CR20) 2013; 31 K Azuma (777_CR113) 2016; 1 K-O Lee (777_CR88) 2014; 74 TS Mok (777_CR5) 2009; 361 MJ Niederst (777_CR15) 2015; 21 S Jenkins (777_CR71) 2017; 12 T Forshew (777_CR129) 2012; 4 Z Zhang (777_CR36) 2012; 44 777_CR116 K Park (777_CR75) 2016; 2 DS-W Tan (777_CR105) 2016; 34 JP Thiery (777_CR42) 2009; 139 J Bean (777_CR111) 2007; 104 DM Murphy (777_CR128) 2015; 33 H Kimura (777_CR72) 2007; 97 RL Siegel (777_CR3) 2016; 66 MG Oser (777_CR37) 2015; 16 KL Reckamp (777_CR127) 2016; 11 JA Engelman (777_CR31) 2007; 316 JY Wu (777_CR79) 2010; 126 777_CR54 JE Chaft (777_CR77) 2011; 17 777_CR106 TJ Lynch (777_CR7) 2004; 350 LG Paz-Ares (777_CR82) 2013; 31 C Escriu (777_CR64) 2016; 8 J Chmielecki (777_CR76) 2011; 3 777_CR102 S Kobayashi (777_CR9) 2005; 352 777_CR104 YL Wu (777_CR6) 2014; 15 DA Belchis (777_CR46) 2016; 7 F Xu (777_CR124) 2012; 5 DS Ettinger (777_CR48) 2017; 15 M Jamal-Hanjani (777_CR56) 2017; 376 JY Douillard (777_CR125) 2014; 9 777_CR69 WL Huang (777_CR59) 2017; 8 M Santarpia (777_CR60) 2016; 10 CP Belani (777_CR108) 2013; 14 S Novello (777_CR47) 2016; 27 J Yang (777_CR93) 2016; 11 K Vishwanathan (777_CR91) 2015; 14 LV Sequist (777_CR99) 2016; 2 HA Yu (777_CR17) 2015; 1 W Fan (777_CR33) 2011; 71 TK Sundaresan (777_CR63) 2016; 22 K Nishie (777_CR74) 2012; 7 K Park (777_CR133) 2016; 11 Y-L Wu (777_CR114) 2016; 34 M Brevet (777_CR122) 2011; 73 JC-H Yang (777_CR96) 2017; 35 JK Lee (777_CR40) 2017; 35 NI Lindeman (777_CR50) 2013; 15 777_CR78 CH Yun (777_CR27) 2008; 105 DR Caswell (777_CR55) 2017; 15 SB Goldberg (777_CR80) 2013; 18 PA Jänne (777_CR92) 2015; 372 K Takezawa (777_CR34) 2012; 2 D Planchard (777_CR90) 2016; 77 N Karachaliou (777_CR130) 2015; 1 C Hu (777_CR126) 2012; 28 TA Yap (777_CR12) 2010; 28 D Li (777_CR13) 2008; 27 S Konagai (777_CR103) 2015; 75 T Takahama (777_CR67) 2016; 7 J Bean (777_CR29) 2008; 14 GR Oxnard (777_CR66) 2016; 34 W Zhou (777_CR87) 2009; 462 BC Liao (777_CR110) 2017; 110 J Yang (777_CR132) 2016; 11 Y Nagai (777_CR131) 2005; 65 JG Paez (777_CR8) 2004; 304 EA Eisenhauer (777_CR21) 2009; 45 777_CR85 SG Wu (777_CR10) 2016; 7 J-J Yang (777_CR26) 2013; 79 F Yamaguchi (777_CR30) 2014; 7 HR Kim (777_CR51) 2013; 32 S Planken (777_CR107) 2017; 60 HA Yu (777_CR134) 2016; 34 C Khoo (777_CR58) 2015; 4 MF Zakowski (777_CR38) 2006; 355 S Jenkins (777_CR70) 2016; 11 K Park (777_CR101) 2016; 34 T Koba (777_CR95) 2017; 96 K Suda (777_CR45) 2011; 6 GR Oxnard (777_CR115) 2015; 33 777_CR97 KD Miller (777_CR1) 2016; 66 M Ignatiadis (777_CR65) 2015; 21 C Chouaid (777_CR53) 2014; 86 MG Kris (777_CR4) 2014; 311 AO Walter (777_CR86) 2013; 3 GV Scagliotti (777_CR81) 2008; 26 DA Cross (777_CR89) 2014; 4 T Shukuya (777_CR24) 2011; 74 TS Mok (777_CR84) 2017; 376 LV Sequist (777_CR35) 2011; 3 LV Sequist (777_CR83) 2015; 372 HN Song (777_CR18) 2016; 11 MN Balak (777_CR28) 2006; 12 K Haratani (777_CR121) 2017; 28 YY Janjigian (777_CR109) 2014; 4 DR Camidge (777_CR112) 2016; 34 777_CR23 777_CR25 K Park (777_CR100) 2015; 33 D Jackman (777_CR22) 2010; 28 N Alam (777_CR39) 2010; 11 H Borghaei (777_CR117) 2015; 373 EL Kwak (777_CR11) 2005; 102 FA Shepherd (777_CR19) 2005; 353 JP Machiels (777_CR14) 2015; 16 RS Herbst (777_CR118) 2016; 387 F Nurwidya (777_CR43) 2012; 44 P Ballard (777_CR94) 2016; 22 JF Gainor (777_CR119) 2016; 22 EA Akbay (777_CR120) 2013; 3 K Taniguchi (777_CR61) 2011; 17 P Bordi (777_CR68) 2015; 4 SI Ou (777_CR52) 2017; 111 MJ Niederst (777_CR41) 2015; 6 HA Yu (777_CR32) 2013; 19 Z Piotrowska (777_CR16) 2017; 35 AG Sacher (777_CR73) 2016; 2 |
| References_xml | – volume: 4 start-page: 126 year: 2015 ident: 777_CR58 publication-title: Transl Lung Cancer Res – volume: 545 start-page: 446 year: 2017 ident: 777_CR57 publication-title: Nature doi: 10.1038/nature22364 – volume: 4 start-page: 1046 year: 2014 ident: 777_CR89 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-14-0337 – volume: 11 start-page: E1 year: 2010 ident: 777_CR39 publication-title: Clin Lung Cancer doi: 10.3816/CLC.2010.n.046 – volume: 65 start-page: 7276 year: 2005 ident: 777_CR131 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-0331 – volume: 462 start-page: 1070 year: 2009 ident: 777_CR87 publication-title: Nature doi: 10.1038/nature08622 – volume: 22 start-page: 5130 year: 2016 ident: 777_CR94 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0399 – volume: 34 start-page: 9055–9055 year: 2016 ident: 777_CR101 publication-title: J Clin Oncol – volume: 11 start-page: S152 year: 2016 ident: 777_CR132 publication-title: J Thorac Oncol doi: 10.1016/S1556-0864(16)30325-2 – volume: 105 start-page: 2070 year: 2008 ident: 777_CR27 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0709662105 – volume: 372 start-page: 1700 year: 2015 ident: 777_CR83 publication-title: N Engl J Med doi: 10.1056/NEJMoa1413654 – volume: 79 start-page: 33 year: 2013 ident: 777_CR26 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.09.016 – volume: 9 start-page: 1345 year: 2014 ident: 777_CR125 publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000263 – volume: 34 start-page: 3375 year: 2016 ident: 777_CR66 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.66.7162 – ident: 777_CR97 doi: 10.1158/1535-7163.MCT-13-0966 – volume: 4 year: 2012 ident: 777_CR129 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3003726 – volume: 35 start-page: 9020–9020 year: 2017 ident: 777_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.15_suppl.9020 – volume: 376 start-page: 629 year: 2017 ident: 777_CR84 publication-title: N Engl J Med doi: 10.1056/NEJMoa1612674 – volume: 15 start-page: 415 year: 2013 ident: 777_CR50 publication-title: J Mol Diagn doi: 10.1016/j.jmoldx.2013.03.001 – volume: 353 start-page: 123 year: 2005 ident: 777_CR19 publication-title: N Engl J Med doi: 10.1056/NEJMoa050753 – volume: 28 start-page: 357 year: 2010 ident: 777_CR22 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.24.7049 – volume: 352 start-page: 786 year: 2005 ident: 777_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa044238 – volume: 34 start-page: 9070–9070 year: 2016 ident: 777_CR112 publication-title: J Clin Oncol – volume: 22 start-page: 1103 year: 2016 ident: 777_CR63 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-1031 – volume: 11 start-page: S152 year: 2016 ident: 777_CR93 publication-title: J Thoracic Oncol doi: 10.1016/S1556-0864(16)30325-2 – ident: 777_CR25 doi: 10.1097/JTO.0b013e3182745948 – ident: 777_CR102 doi: 10.1111/bjd.15935 – volume: 35 start-page: 3065 year: 2017 ident: 777_CR40 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.71.9096 – volume: 19 start-page: 2240 year: 2013 ident: 777_CR32 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-2246 – volume: 77 start-page: 767 year: 2016 ident: 777_CR90 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-016-2992-z – volume: 1 start-page: e000063 year: 2016 ident: 777_CR113 publication-title: ESMO Open doi: 10.1136/esmoopen-2016-000063 – volume: 5 start-page: 439 year: 2012 ident: 777_CR124 publication-title: Onco Targets Ther – volume: 17 start-page: 6298 year: 2011 ident: 777_CR77 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1468 – volume: 346 start-page: 92 year: 2002 ident: 777_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa011954 – volume: 387 start-page: 1540 year: 2016 ident: 777_CR118 publication-title: Lancet doi: 10.1016/S0140-6736(15)01281-7 – volume: 110 start-page: 7 year: 2017 ident: 777_CR110 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2017.05.009 – volume: 3 start-page: 1404 year: 2013 ident: 777_CR86 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0314 – volume: 27 start-page: v1 year: 2016 ident: 777_CR47 publication-title: Ann Oncol doi: 10.1093/annonc/mdw326 – volume: 33 start-page: 8084–8084 year: 2015 ident: 777_CR100 publication-title: J Clin Oncol – volume: 60 start-page: 3002 year: 2017 ident: 777_CR107 publication-title: J Med Chem doi: 10.1021/acs.jmedchem.6b01894 – volume: 15 start-page: 213 year: 2014 ident: 777_CR6 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70604-1 – volume: 372 start-page: 1689 year: 2015 ident: 777_CR92 publication-title: N Engl J Med doi: 10.1056/NEJMoa1411817 – volume: 11 start-page: 1690 year: 2016 ident: 777_CR127 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.05.035 – volume: 7 start-page: 1722 year: 2012 ident: 777_CR74 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e31826913f7 – volume: 20 start-page: 1698 year: 2014 ident: 777_CR62 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-2482 – volume: 34 start-page: 9020–9020 year: 2016 ident: 777_CR114 publication-title: J Clin Oncol – volume: 4 start-page: 584 year: 2015 ident: 777_CR68 publication-title: Transl Lung Cancer Res – volume: 21 start-page: 3924 year: 2015 ident: 777_CR15 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-0560 – volume: 7 start-page: 58492 year: 2016 ident: 777_CR67 publication-title: Oncotarget doi: 10.18632/oncotarget.11303 – volume: 66 start-page: 7 year: 2016 ident: 777_CR3 publication-title: CA Cancer J Clin doi: 10.3322/caac.21332 – volume: 15 start-page: 133 year: 2017 ident: 777_CR55 publication-title: BMC Med doi: 10.1186/s12916-017-0900-y – volume: 10 start-page: 417 year: 2016 ident: 777_CR60 publication-title: Biomark Med doi: 10.2217/bmm.16.6 – volume: 17 start-page: 7808 year: 2011 ident: 777_CR61 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1712 – volume: 16 start-page: e165 year: 2015 ident: 777_CR37 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71180-5 – volume: 11 start-page: e45 year: 2016 ident: 777_CR18 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2015.12.093 – volume: 111 start-page: 61 year: 2017 ident: 777_CR52 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2017.07.006 – volume: 31 start-page: 3327 year: 2013 ident: 777_CR20 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.44.2806 – volume: 27 start-page: 2653 year: 2009 ident: 777_CR123 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.3930 – volume: 11 start-page: S113 year: 2016 ident: 777_CR133 publication-title: J Thorac Oncol doi: 10.1016/S1556-0864(16)30243-X – volume: 183 start-page: 1071 year: 2011 ident: 777_CR44 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201009-1440OC – volume: 8 start-page: 2357 year: 2016 ident: 777_CR64 publication-title: J Thorac Dis doi: 10.21037/jtd.2016.07.96 – volume: 74 start-page: 457 year: 2011 ident: 777_CR24 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2011.04.007 – ident: 777_CR85 doi: 10.1056/NEJMe1500181 – volume: 16 start-page: 583 year: 2015 ident: 777_CR14 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70124-5 – volume: 74 start-page: LB-100-LB-100 year: 2014 ident: 777_CR88 publication-title: Cancer Research – volume: 104 start-page: 20932 year: 2007 ident: 777_CR111 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0710370104 – volume: 33 start-page: 2509–2509 year: 2015 ident: 777_CR115 publication-title: J Clin Oncol – volume: 311 start-page: 1998 year: 2014 ident: 777_CR4 publication-title: JAMA doi: 10.1001/jama.2014.3741 – volume: 21 start-page: 4786 year: 2015 ident: 777_CR65 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1190 – ident: 777_CR116 doi: 10.1016/S1556-0864(16)30246-5 – volume: 18 start-page: 1214 year: 2013 ident: 777_CR80 publication-title: Oncologist doi: 10.1634/theoncologist.2013-0168 – volume: 34 start-page: 9050–9050 year: 2016 ident: 777_CR134 publication-title: J Clin Oncol – volume: 316 start-page: 1039 year: 2007 ident: 777_CR31 publication-title: Science doi: 10.1126/science.1141478 – volume: 14 start-page: 557 year: 2013 ident: 777_CR108 publication-title: Cancer Biol Ther doi: 10.4161/cbt.24598 – volume: 28 start-page: 1532 year: 2017 ident: 777_CR121 publication-title: Ann Oncol doi: 10.1093/annonc/mdx183 – volume: 27 start-page: 4702 year: 2008 ident: 777_CR13 publication-title: Oncogene doi: 10.1038/onc.2008.109 – volume: 3 year: 2011 ident: 777_CR35 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3002003 – volume: 44 start-page: 852 year: 2012 ident: 777_CR36 publication-title: Nat Genet doi: 10.1038/ng.2330 – volume: 44 start-page: 151 year: 2012 ident: 777_CR43 publication-title: Cancer Res Treat doi: 10.4143/crt.2012.44.3.151 – volume: 28 start-page: 3965 year: 2010 ident: 777_CR12 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.26.7278 – volume: 26 start-page: 3543 year: 2008 ident: 777_CR81 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.0375 – volume: 1 start-page: 982 year: 2015 ident: 777_CR17 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.1066 – volume: 7 start-page: 45237 year: 2016 ident: 777_CR46 publication-title: Oncotarget doi: 10.18632/oncotarget.9931 – volume: 376 start-page: 2109 year: 2017 ident: 777_CR56 publication-title: N Engl J Med doi: 10.1056/NEJMoa1616288 – volume: 75 start-page: 2586–2586 year: 2015 ident: 777_CR103 publication-title: Cancer Res doi: 10.1158/1538-7445.AM2015-2586 – volume: 14 start-page: 7519 year: 2008 ident: 777_CR29 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0151 – volume: 6 start-page: 6377 year: 2015 ident: 777_CR41 publication-title: Nat Commun doi: 10.1038/ncomms7377 – volume: 139 start-page: 871 year: 2009 ident: 777_CR42 publication-title: Cell doi: 10.1016/j.cell.2009.11.007 – ident: 777_CR69 – volume: 32 start-page: 50 year: 2013 ident: 777_CR51 publication-title: J Exp Clin Cancer Res doi: 10.1186/1756-9966-32-50 – volume: 15 start-page: 504 year: 2017 ident: 777_CR48 publication-title: J Natl Compr Cancer Netw doi: 10.6004/jnccn.2017.0050 – volume: 96 start-page: e6087 year: 2017 ident: 777_CR95 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000006087 – volume: 31 start-page: 2895 year: 2013 ident: 777_CR82 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.47.1102 – ident: 777_CR78 doi: 10.1200/JCO.2017.73.9250 – volume: 4 start-page: 1036 year: 2014 ident: 777_CR109 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-14-0326 – volume: 2 start-page: 541 year: 2016 ident: 777_CR99 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.5009 – volume: 12 start-page: 6494 year: 2006 ident: 777_CR28 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-1570 – volume: 8 start-page: 18590 year: 2017 ident: 777_CR59 publication-title: Oncotarget doi: 10.18632/oncotarget.14613 – volume: 66 start-page: 271 year: 2016 ident: 777_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21349 – volume: 1 start-page: 149 year: 2015 ident: 777_CR130 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2014.257 – volume: 35 start-page: 2020–2020 year: 2017 ident: 777_CR96 publication-title: J Clin Oncol – volume: 34 start-page: 9044–9044 year: 2016 ident: 777_CR105 publication-title: J Clin Oncol – volume: 11 start-page: S153 year: 2016 ident: 777_CR70 publication-title: J Thorac Oncol doi: 10.1016/S1556-0864(16)30327-6 – volume: 2 start-page: 305 year: 2016 ident: 777_CR75 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.4921 – volume: 14 start-page: B153-B153 year: 2015 ident: 777_CR91 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.TARG-15-B153 – volume: 45 start-page: 228 year: 2009 ident: 777_CR21 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 102 start-page: 7665 year: 2005 ident: 777_CR11 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0502860102 – volume: 355 start-page: 213 year: 2006 ident: 777_CR38 publication-title: N Engl J Med doi: 10.1056/NEJMc053610 – volume: 350 start-page: 2129 year: 2004 ident: 777_CR7 publication-title: N Engl J Med doi: 10.1056/NEJMoa040938 – volume: 71 start-page: 4494 year: 2011 ident: 777_CR33 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-2668 – volume: 2 start-page: 922 year: 2012 ident: 777_CR34 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0108 – volume: 6 start-page: 1152 year: 2011 ident: 777_CR45 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e318216ee52 – volume: 33 start-page: e22086-e22086 year: 2015 ident: 777_CR128 publication-title: J Clin Oncol – volume: 73 start-page: 96 year: 2011 ident: 777_CR122 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2010.10.014 – volume: 12 start-page: 1061 year: 2017 ident: 777_CR71 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.04.003 – volume: 304 start-page: 1497 year: 2004 ident: 777_CR8 publication-title: Science doi: 10.1126/science.1099314 – ident: 777_CR106 doi: 10.1016/j.jtho.2016.11.510 – ident: 777_CR23 doi: 10.1016/j.cllc.2013.10.001 – ident: 777_CR54 doi: 10.1016/j.jfma.2017.04.018 – volume: 3 start-page: 1355 year: 2013 ident: 777_CR120 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0310 – volume: 126 start-page: 247 year: 2010 ident: 777_CR79 publication-title: Int J Cancer doi: 10.1002/ijc.24657 – volume: 7 start-page: 12404 year: 2016 ident: 777_CR10 publication-title: Oncotarget doi: 10.18632/oncotarget.7189 – volume: 7 start-page: 357 year: 2014 ident: 777_CR30 publication-title: Oncol Lett doi: 10.3892/ol.2013.1705 – volume: 366 start-page: 883 year: 2012 ident: 777_CR49 publication-title: N Engl J Med doi: 10.1056/NEJMoa1113205 – volume: 2 start-page: 1014 year: 2016 ident: 777_CR73 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.0173 – ident: 777_CR104 doi: 10.1158/1078-0432.CCR-17-1447 – volume: 97 start-page: 778 year: 2007 ident: 777_CR72 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603949 – volume: 373 start-page: 1627 year: 2015 ident: 777_CR117 publication-title: N Engl J Med doi: 10.1056/NEJMoa1507643 – volume: 86 start-page: 170 year: 2014 ident: 777_CR53 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2014.08.016 – volume: 361 start-page: 947 year: 2009 ident: 777_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa0810699 – volume: 3 year: 2011 ident: 777_CR76 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3002356 – volume: 22 start-page: 4585 year: 2016 ident: 777_CR119 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-3101 – volume: 374 start-page: 2296 year: 2016 ident: 777_CR98 publication-title: N Engl J Med doi: 10.1056/NEJMc1602688 – volume: 28 start-page: 1815 year: 2012 ident: 777_CR126 publication-title: Oncol Rep doi: 10.3892/or.2012.1987 |
| SSID | ssj0017874 |
| Score | 2.6583474 |
| SecondaryResourceType | review_article |
| Snippet | Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver... Abstract Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 38 |
| SubjectTerms | Animals Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Care and treatment Complications and side effects Development and progression Diagnosis Dosage and administration Drug Resistance, Neoplasm - genetics ErbB Receptors - genetics ErbB Receptors - metabolism Gefitinib Humans Lung cancer, Non-small cell Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Protein Kinase Inhibitors - therapeutic use Review |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1PaxUxEB-kUPEitv5brSWCIAih2Wyymxyr9LUq9SAt9BbSbKKF133S93roze_gN_STOLPZ93yL0F687iRskvll_iSTGYA3Jar0aOjEXYvElRGRexsF9wiekqpMakkPnI-_1Een6tOZPlsr9UUxYTk9cF64PbIQTKpbEWqtgq28VijWrZeVTlS_laQv6rylMzXcHyAM1XCHWZp6b45aTVHckOGiaRpejrRQn6z_X5G8ppPG8ZJrCmjyCB4OliPbzyPegnux24bNXEvyZhvuHw-35I_h29-YFjZLzAeK9o0tQ8-arEVkM1vM2MHh5Cs7-fzx989fORwcW-TXWDfsomPL4ADWzTo-v_TTKaNDfjZF6cACka6ewOnk4OTDER8KKvCgrVlwFWqJFp9IMnrU7VWTIvqnFm2GaJskpEdvUIYY2qqO0aNqIwshaYnyXJ4juXoKG_jT-BxYsk1svdDISqOMbpG3QbStiXUV21KFAsRygV0Yso1T0Yup670OU7vME4c8ccQTVxbwbtXlR061cVvj98S1VUPKkt1_QOy4ATvuLuwU8JZ47mgv4-CCH54k4BQpK5bbx-4liSlZwM6oJe7BMCK_XqLGEYkC17o4u55TlU96e2xFVcCzjKLVmHFKGu1pUUAzwtdoUmNKd_G9TwGuDUFcvPgfq_ASHsh-Z0he2h3YWFxdx1doaS3Od_tN9QeuzyKs priority: 102 providerName: Directory of Open Access Journals |
| Title | Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29455650 https://www.proquest.com/docview/2004394903 https://pubmed.ncbi.nlm.nih.gov/PMC5817870 https://doaj.org/article/83528f6d0c654c93a54eed9a235f0375 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Rb9MwELbGJhAvCAaMwKiMhISEZHAcO3YeEOpQyyjqhMYq9c3yHGdMCim0nUTf-A_8Q34Jd0naLWJC4qlSzklj33e-u9z5jpDnMaj0YPCLu-IFk4YH5rLAmQPwxNhlUgk84Dw-Sg8ncjRV0y2ybm_VLuDiWtcO-0lN5uWrH99Xb0Hg39QCb9LXC9BZErOCDONaawbO0A4oJo2dHMbyMqgA2KyDzFKnTKrMtEHOax_RUVN1Nf-_9-wrSqubUHlFQw3vkjutaUn7DRbuka1Q7ZKbTbPJ1S65NW7D6PfJ2WXSC50V1HlMBw45BdcbzUnAAV3O6OD98JiefPzw--evJl8cRjTHtVb0vKLr7AFazSq2-OrKkmIUgJawfVCPpPkDMhkOTt4dsrbjAvOwHksmfSrAJOSFCA6Uf6KLAA5sBkZFyHTBhQN3Ufjg8yQNwYHuQxOiUAI2fHEK5OQh2YY_DY8ILTIdcscV8NpIo3Jgvud5bkKahDyWPiJ8vcDWt-XIsStGaWu3xKS24YkFnljkiY0j8nJzy7emFse_Bh8g1zYDsYx2fWE2P7OtVFo0P02R5tynSvoscUqCzZA5kagCmwNH5AXy3CL84OW8a88swBSxbJbtw-0x7mMiIvudkSCkvkN-tkaNRRJmtlVhdrHANqB4ODnjSUT2GhRt3hmmpMDg5hHRHXx1JtWlVOdf6hrhyiDc-eP_WbIn5LaoJUCwONsn28v5RXgKJtfytEdu6KnukZ1-f_R5BL8Hg6NPx736A0avFrI_a7coRg |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Management+of+acquired+resistance+to+EGFR+TKI%E2%80%93targeted+therapy+in+advanced+non-small+cell+lung+cancer&rft.jtitle=Molecular+cancer&rft.au=Wu%2C+Shang-Gin&rft.au=Shih%2C+Jin-Yuan&rft.date=2018-02-19&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=17&rft.issue=1&rft_id=info:doi/10.1186%2Fs12943-018-0777-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12943_018_0777_1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon |